Package Leaflet: Information for the User
Oxcarbazepine Cinfa600 mg Film-Coated Tablets
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
The active ingredient of oxcarbazepina cinfa is oxcarbazepina.
Oxcarbazepina belongs to a group of medicines called anticonvulsants or antiepileptics.
What is oxcarbazepina cinfa used for
Medicines like oxcarbazepina are the standard treatment for epilepsy.
Epilepsy is a brain disorder that causes people to have recurring seizures and convulsions. Seizures occur due to a temporary failure in the electrical activity of the brain. Normally, brain cells coordinate the body's movements by sending signals through muscle nerves in an orderly organized manner. In epilepsy, brain cells send too many signals in a disorganized manner. The result can be uncoordinated muscle activity known as an epileptic seizure.
Oxcarbazepina is used to treat partial seizures with or without secondary generalization with tonic-clonic seizures. Partial seizures involve a limited area of the brain, but can extend to the entire brain and produce generalized tonic-clonic seizures. There are 2 types of partial seizures: simple and complex. In simple partial seizures, the patient remains conscious, while in complex partial seizures, the level of consciousness is altered.
Oxcarbazepina acts by keeping the brain's "hyperexcited" nerve cells under control, suppressing or reducing the frequency of these seizures.
Oxcarbazepina may be used alone or in combination with other antiepileptic medications. Normally, the doctor will try to find the medication that works best for you or your child. However, in severe epilepsy, you may need a combination of two or more medications to control your seizures. Oxcarbazepina is indicated for use in adults and children aged 6 or older.
If you have any doubts about how oxcarbazepina works or why you have been prescribed this medication, consult your doctor.
Follow all the instructions given by your doctor carefully, even if they differ from the general information provided in this leaflet.
Monitoring during treatment with oxcarbazepine
Your doctor may perform a blood test before and during treatment with oxcarbazepine to determine your dose. Your doctor will tell you when to have the blood tests.
Do not take oxcarbazepine cinfa
If you are allergic, inform your doctor before taking oxcarbazepine. If you think you are allergic, ask your doctor.
Warnings and precautions
Consult your doctor or pharmacist before starting to take oxcarbazepine cinfa
The risk of severe skin reactions in Han Chinese or Thai patients associated with carbamazepine or chemically related compounds can be predicted by blood tests. Your doctor will advise if a blood test is necessary before taking oxcarbazepine.
If you experience any of the following symptoms after taking oxcarbazepine, inform your doctor immediately or go to the nearest hospital emergency department:
Children and adolescents
For treatment in children, your doctor may recommend monitoring thyroid function before and during treatment.
Other medicines and oxcarbazepine cinfa
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine.
Especially in the case of:
Taking oxcarbazepine cinfa with food, drinks, and alcohol
Oxcarbazepine can be taken with or without food. During treatment with oxcarbazepine, avoid drinking alcohol, as it may increase the sedative effects of this medicine; if in doubt, consult your doctor.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medicine.
Pregnancy
It is essential to control seizures during pregnancy. However, there may be a risk to your baby if you take antiepileptic medicines during pregnancy.
Birth defects
Studies have not shown an increased risk of birth defects associated with oxcarbazepine administered during pregnancy, however, it cannot be ruled out that there may be a risk of birth defects in the fetus.
Neurological development disorders
Some studies have shown that exposure to oxcarbazepine in the womb affects the development of brain function (neurological development) in children, while in other studies this effect has not been observed. The possibility of an effect on neurological development cannot be ruled out.
Your doctor will inform you of the benefits and potential risks of treatment and help you decide whether to take oxcarbazepine.
Do not stop taking oxcarbazepine without consulting your doctor.
Breastfeeding
If you are taking this medicine, consult your doctor before starting breastfeeding. The active ingredient in oxcarbazepine cinfa passes into breast milk. Although available data suggest that the amount of oxcarbazepine cinfa that passes to the breastfeeding baby is low, a risk of adverse effects in the baby cannot be ruled out.
Your doctor will inform you of the benefits and potential risks of breastfeeding while taking oxcarbazepine cinfa. If you are breastfeeding during treatment with oxcarbazepine cinfa and believe your baby is experiencing any adverse effects, such as excessive sleepiness or poor weight gain, inform your doctor immediately.
Driving and operating machinery
Oxcarbazepine may cause symptoms such as drowsiness, dizziness, or visual disturbances, and may impair your ability to react. These effects, as well as the underlying condition, may make it difficult for you to drive vehicles or operate machinery. Therefore, do not drive, operate machinery, or engage in other activities that require special attention, until your doctor assesses your response to this medicine.
How much to take
Use in adults
Use in children
Oxcarbazepine can be used in children 6 years of age or older. The recommended dose for children is calculated based on weight.
How to take oxcarbazepine cinfa
When and for how long to take oxcarbazepine cinfa
Take oxcarbazepine twice a day every day, approximately at the same time of day, unless your doctor tells you otherwise. This will have the best effect in controlling epilepsy. It will also help you remember when to take the tablet or tablets.
Your doctor will inform you how long your treatment or that of your child will last. The duration of treatment will depend on the type of seizure you or your child suffer from. It may be necessary to continue treatment for several years to control seizures. Do not change the dose or stop treatment without first talking to your doctor.
If you take more oxcarbazepine cinfa than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested. The symptoms of overdose with oxcarbazepine may include:
If you forget to take oxcarbazepine cinfa
If you have forgotten a single dose, take it as soon as you can, except if it is almost time for the next one; in this case, wait and return to the recommended administration schedule.
If you are unsure or have forgotten several doses, inform your doctor.Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with oxcarbazepine cinfa
Do not stop taking your medication without first consulting your doctor.
To prevent a sudden worsening of seizures, do not stop treatment abruptly. If you interrupt your treatment, it should be done gradually as your doctor has indicated.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may cause side effects, although not everyone will experience them.
Inform your doctor immediately or go to the nearest hospital emergency service if any of the following side effects occur:
The following are symptoms of potentially serious side effects that may require urgent medical treatment.
Your doctor will decide whether to immediately stop treatment with oxcarbazepine and how to continue your treatment in the future.
Rare(may affect up to 1 in 100 people):
Very rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Inform your doctor as soon as possible if you experience any of the following side effects.They may require medical attention.
Common(may affect up to 1 in 10 people):
Very rare(may affect up to 1 in 10,000 people):
Other side effects that may occur
These are mild to moderate side effects of oxcarbazepine. Most of these side effects are transient and usually decrease over time.
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Rare(may affect up to 1 in 100 people):
Very rare(may affect up to 1 in 1,000 people):
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keepthis medicationout of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and the blister pack after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Do not use this medication if you observe that the packaging is damaged or shows signs of manipulation.
Medications should not be disposed of through drains or in the trash.Deposit the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Oxcarbazepine cinfa composition
Tablet core;microcrystalline cellulose, povidone K30, crospovidone, anhydrous colloidal silica, and magnesium stearate.
Tablet coating;hypromellose, titanium dioxide (E-171), and macrogol.
It also contains iron oxide red (E-172).
Product appearance and packaging contents
Coated, oblong, non-scored, and pale pink tablets.
Coated tablets with a film coating are presented in blisters. Each package contains 50, 100, or 500 (clinical package) tablets.
Only some package sizes may be commercially available.
Marketing authorization holder and manufacturer
Cinfa Laboratories, S.A.
Carretera Olaz-Chipi, 10. Areta Industrial Estate
31620 Huarte (Navarra) - Spain
Last review date of this leaflet:October 2022
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
You can access detailed and updated information about this medication by scanning the QR code included in the leaflet and packaging with your smartphone. You can also access this information at the following internet address:https://cima.aemps.es/cima/dochtml/p/77723/P_77723.html
QR code link to:https://cima.aemps.es/cima/dochtml/p/77723/P_77723.html
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.